Pay in 4 interest-free payments of $5.44 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
Retrieved 24 October 2017
Altimmune Sector: Dual GLP-1/glucagon receptor agonists for obesity and liver disease HQ: Gaithersburg, MD Year Founded: 1997 Origin Story: Altimmune originally focused on infectious disease vaccines and biodefense, including a formative all-stock merger with PharmAthene, a US biodefense drug specialist
GLP-1: Miracle, Myth, or Metabolic Reset
Current NICE guidance (NG28 for type 2 diabetes, TA875 for semaglutide 2.4mg, and TA664 for liraglutide 3.0mg) does not include inflammatory conditions as indications
US$ 23.71
US$ 20.74
US$ 25.10
US$ 29.10
US$ 29.84
